Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.45 |
| ▸ | PGR | P06401 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1363936 | 1.00 | AR (0.45) | ARPGRMAOAMAOBMEN1 | |
| SCHEMBL12140389 | 0.92 | AR (0.43) | ARPGRMAOAMAOBMEN1 | |
| SCHEMBL1364779 | 0.91 | ALDH1A1 (0.39) | ARPGRALDH1A1PKM | |
| SCHEMBL1364781 | 0.91 | ALDH1A1 (0.39) | ARPGRALDH1A1PKM | |
| SCHEMBL15713150 | 0.89 | MAOA (0.39) | ARPGRMAOAMAOBMEN1 | |
| SCHEMBL12140321 | 0.88 | MAOA (0.38) | ARPGRMAOAMAOBMEN1 | |
| SCHEMBL12138631 | 0.86 | — | — | |
| SCHEMBL13748286 | 0.84 | AR (0.37) | ARPGRALDH1A1NR3C2NR3C1 | |
| SCHEMBL1365014 | 0.84 | AR (0.42) | ARPGRMAOAMAOBEPHX2 | |
| SCHEMBL1365443 | 0.84 | AR (0.42) | ARPGRMAOAMAOBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260028-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2260028-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8629167-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629167-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8455525-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455525-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130116288-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116288-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8268872-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8067448-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067448-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100041721-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090253758-A1 | Selective androgen receptor modulators | ELLIPSES PHARMA LTD (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253758-A1 | Selective androgen receptor modulators | ELLIPSES PHARMA LTD (GB) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041721-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, IGF1R | AR 1/4885PGR 16/4885MAOA 2322/4885 |
| US-20130116288-A1 | Selective Androgen Receptor Modulators | AR, SHBG, IGF1R | AR 1/4885PGR 17/4885MAOA 2317/4885 |
| US-20090253758-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | AR 1/4885PGR 28/4885MAOA 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.